Drug-Drug Interactions

Size: px
Start display at page:

Download "Drug-Drug Interactions"

Transcription

1 Slide 1 Drug-Drug Interactions David Back University of Liverpool UK David Back University of Liverpool C-Hep Berlin October 2012

2 Interactions with the new HepC drugs are challenging! Slide 2 Number of known interactions Number of potential interactions (based on metabolic profile) Magnitude of the interactions Applying data from Healthy Volunteer studies to HCV patients

3 What can we learn from other therapeutic areas: HIV? Slide 3 Most DDIs are manageable or avoidable - if recognised DDIs may be: - Anticipated - Unanticipated, but explainable - Unanticipated and inexplicable Most potential interactions remain unstudied PK effect clinically significant effect - Therapeutic window

4 The importance of the Therapeutic Window Slide 4 Conc Conc Toxicity Toxicity 2 fold 2 fold X 30% X 30% Compromise Efficacy Compromise Efficacy Narrow Therapeutic Window Wide Therapeutic Window

5 Key Mechanisms of Drug Interactions: Alteration of steady state of a drug in the regimen Enzyme Inhibition or Interaction with transporter Slide 5 Interacting Drug Days

6 Key Mechanisms of Drug Interactions: Alteration of steady state of a drug in the regimen Enzyme Inhibition or Interaction with transporter Enzyme Induction or Interaction with transporter or Binding displacement Slide 6 Interacting Drug Interacting Drug Days Days

7 Telaprevir and Boceprevir are metabolised by and strongly inhibit CYP3A4 Slide 7 CYP 3A isozymes are the most abundant in the liver CYP 3A isozymes involved in the metabolism of majority of drugs CYP 1A2 CYP 2A6 CYP 2B6 CYP 2C8 CYP 2C9 CYP 2C8 CYP 2B6 CYP 2C9 CYP 2A6 CYP 1A2 CYP 2C19 CYP 2D6 CYP 3A CYP 2C19 CYP 2D6 CYP 3A CYP 2E1 CYP 2E1 Proportion of total CYP enzymes present in human liver Proportion of drugs that are substrates for major CYP enzymes Boceprevir also metabolised by Aldo-Keto Reductase (AKR) CYP: cytochrome P450 Hacker MP, et al. Pharmacology: Principles and All percentages are approximate. For illustrative purposes, Practice. Academic Press 2009 hepatic CYP enzymes present at <5% are all represented as 3.3%

8 Telaprevir & Boceprevir increase exposure to CYP3A substrates: Perpetrator Slide 8 Drug TVR effect on the AUC (exposure) BOC effect on the AUC (exposure) Cyclosporine A 4.6-fold increase 2.7-fold increase Manageable Tacrolimus 70-fold More increase challenging to 17-fold manage increase Midazolam 3.4-fold increase (i.v) 9-fold increase (oral) CI CI 6.3-fold increase (oral) Atorvastatin 7.9-fold increase 2.3-fold increase Amlodipine 2.79-fold? CI Dose reduce Dose reduce Dose reduce? Garg V, et al. Heptatology 2011:54:20 27; Garg V, et al. J Clin Pharmacol 2012 ; Lee JE, et al. Antimicrob Agents Chemother 2011;55: ; Telaprevir SmPC; Hulskotte EGJ et al HEPDart 2011; Abs 122 and Abs 123; Kessara C et al, CROI 2011, Abs 118; Boceprevir SmPC

9 Changes in immunosuppression during the first 12 weeks of TVR-based therapy Slide 9 Immunosuppression Patients (N) Daily dose at baseline mg ± SD Av daily dose during triple therapy mg ± SD Av daily dose reduction Tacrolimus ± ± (5-33.6) Sirolimus Cyclosporin ± ± (2-3.8) Werner CR et al Liver Transplantation 2012 (Epub ahead of print)

10 Slide 10 In the absence of specific DDI data we need to understand the metabolic profiles of drugs in the regimen in order to determine the potential for interaction

11 Interaction of Lipid Lowering Agents with TVR & BOC Slide 11 Drug Major Clearance Pathway Effect of TVR Effect of BOC Atorvastatin CYP3A4, OATP1B1 D D Lovastatin CYP3A4 Simvastatin CYP3A4 Pravastatin OATP1B1/3 D Rosuvastatin CYP2C9 (minor); OATP1B1 Fluvastatin CYPs(Multiple); OATP1B1/ 2B1 Pitavastatin (US) CYP2C9 (minor) UGT1A3; OATP1A2/1B3 Gemfibrozil D = Data from study Enzymes unknown From or individual SPCs

12 Interaction of Lipid Lowering Agents with TVR & BOC Drug Major Clearance Pathway Effect of TVR Effect of BOC Slide 12 Atorvastatin CYP3A4, OATP1B1 D D Lovastatin CYP3A4 Simvastatin CYP3A4 Pravastatin OATP1B1/3 D Rosuvastatin CYP2C9 (minor); OATP1B1 Fluvastatin CYPs(Multiple); OATP1B1/ 2B1 Pitavastatin (US) CYP2C9 (minor) UGT1A3; OATP1A2/1B3 Gemfibrozil D = Data from study Enzymes unknown Contraindication or Caution when co-administering statins with CYP3A4 mediated metabolism but can you avoid using a statin during DAA treatment? From or individual SPCs

13 Slide 13 If clearance involves just CYP3A4 co-med levels will increase. But if other additional metabolic pathways co-med levels could decrease. Also note other interaction mechanisms.

14 Telaprevir & Boceprevir decrease exposure of other CYP-metabolised drugs: Perpetrator Slide 14 TVR effect BOC effect Co-medication Escitalopram (SSRI) Metabolised by CYP2C19 & CYP3A4 AUC AUC 35% 21% Mechanism: Not clearly determined but INDUCTION of CYP2C19? Doses may need to be increased when combined with telaprevir Dose adjustment not anticipated with boceprevir. van Heeswijk R, et al. IWCPHT Abstract 12; Telaprevir SmPC; Hulskotte EGJ et al HEP Dart 2011; Abs 121; Boceprevir SmPC.

15 Other antidepressants that have not been studied with telaprevir Slide 15 Antidepressants metabolized by CYP 3A4 Antidepressants metabolized primarily by non CYP 3A4

16 HIV-HCV co-infection Slide 16

17 Telaprevir & Boceprevir decrease exposure of HIV protease inhibitors Perpetrator Slide 17 Boosted PI % Change in AUC of Boosted PI by BOC % Change in AUC of Boosted PI by TVR Atazanavir/r 35% 17% Lopinavir/r 34% Darunavir/r 44% 32% Mechanism? CYP3A4 is inhibited by ritonavir; induction of another pathway Displacement from protein binding and increased clearance Van Heeswijk R et al CROI 2011; Abs 119; Telaprevir SmPC Hulskotte E et al; CROI 2012 Abs 771LB

18 Telaprevir and boceprevir are also Victims of drug interactions: HIV drugs Slide 18 Effect on Boceprevir Effect on Telaprevir Co-medication AUC AUC Efavirenz (600 mg qd) 19% (Cmin 44%) 26% Atazanavir/r 20% Darunavir/r 32% 35% Lopinavir/r 45% 54% Telaprevir SmPC; van Heeswijk R et al, CROI 2011; Abstract 119. Modified from Kassera C, et al. CROI Abstract 118 Boceprevir SmPC

19 But what if the HCV PI and HIV PI interaction was similar to TVR-Methadone?: During telaprevir co-administration vs methadone alone: Total C min of R-methadone reduced by 31% Free fraction of R-methadone increased by 26% No change in the unbound (effective) concentration of R-methadone 15 Total C min of R- methadone (ng/ml) Methadone Methadone + TVR Median free fraction of R-methadone (%) Methadone Methadone + TVR Median unbound R- methadone C min (ng/ml) Protein Binding Displacement Methadone Methadone + TVR van Heeswijk R, et al. J Hepatol 2011;54(Suppl. 1):S491

20 Slide 20 So... Although total concentrations are reduced the free concentrations may be less affected need more data! AND... Is the magnitude of the interaction different in HCV patients?

21 Most DDI studies are in Healthy Subjects: Physiological Changes (vs. healthy volunteers) Parameter HCV-infected Albumin * 1 α1-acid glycoprotein 3 Gastric ph 4 Cytokines 6 Cytochrome P450 s 5 * Magnitude of effect dependent on stage of liver involvement Also hemodynamic changes with hepatic impairment Slide 21 1 Nagao Y & Sata M. Virology Journal 2010; 7: 375; 2 Monga HK et al. Clin Infect Dis 2001; 33: 240-7; 3 Ozeki T et al. Br J Exp Path 1988; 69: ; 4 Nam YJ et al. Korean J Hepatol 2004; 10: ; 5 Frye RF et al. Clinical Pharmacol Ther 2006; 80: ; 6 Huang et al Clin Pharmacol Ther 2010; 87: 32-36

22 Slide 22 Differences in CYP enzymes in patients with hepatic impairment Chlorzoxazone 100 CYP3A4 Caffeine Debrisoquine % of control Mephenytoin 0 CP-A (6) CP-B (21) CP-C (21)* Model of hepatic dysfunction and implications for clearance of drugs predominantly metabolized by CYP pathway in liver. Study in healthy volunteers and patients with liver disease Frye RF et al. Clinical Pharmacol Ther 2006; 80: Johnson TN et al. Clinical Pharmacokin 2010; 49:

23 Slide 23 Patient 1. On darunavir/r 800/100 mg QD monotherapy Liver cirrhosis (liver stiffness 34kPa) DRV concentration at wk 5 of HCV therapy with BOC 3777 ng/ml (normal range) Patient 2. On fos-amprenavir/r 700/100 mg BID containing regimen Liver cirrhosis (liver stiffness 32kPa) FPV concentration at wk 8 of HCV therapy with BOC 1699 ng/ml (normal range)

24 Contraception Slide 24

25 Slide 25 Telaprevir & Boceprevir alter exposure of contraceptive steroids Additional methods of non-hormonal contraception should be used; ie hormonal contraceptives may be continued but may not be reliable during and immediately following TVR dosing. During this time, female patients of childbearing potential should use two effective non-hormonal methods of contraception. Potential compromised contraceptive efficacy Caution should be exercised in patients predisposed to hyperkalaemia. Garg V, et al. IWCPHT Abstract PK_17Telaprevir EU SmPC; Kassera C et al CROI 2011; Abs 118; Boceprevir EU SmPC.

26 What about the Mirena IUD and TVR? Slide 26 The metabolism of progestogens may be increased by concomitant use of substances known to induce drugmetabolising enzymes, specifically cytochrome P450 enzymes, such as anti-infectives (e.g. rifampicin, rifabutin, nevirapine, efavirenz) 1. The influence of these drugs on the contraceptive efficacy of Mirena is not known, but it is not believed to be of major importance due to the local mechanism of action

27 DDI management: a stepwise approach Be vigilant for DDIs when starting PI-based therapy Check all patient s concomitant drugs (prescribed/otc) and herbal products Consult the SmPCs of PIs Consult on-line resources and a pharmacist/ pharmacologist to seek guidance Slide 27

28 Slide 28

29 Slide 29 What about the second generation of drugs?

30 Drug Interactions with Simeprevir (TMC435) Drug Effect of TMC435 Effect of Drug on TMC435 Methadone (CYP3A4 & CYP2B6) Escitalopram (CYP2C19) Efavirenz (CYP2B6) Rilpivirine (CYP3A4) Raltegravir (UGTs) No effect na No effect na na 70% 12% No effect No effect 11% Na = not assessed Overall weaker inhibitory effect on CYP enzymes Simmen K et al Int Liver Congress Hong Kong 2008; Abs 507. Beumont-Mauviel M et al AASLD 2011; Abs 1353 & 1354

31 Drug Interactions with Faldaprevir (BI201355) Drug Oral Midazolam (CYP3A4) Omeprazole (CYP2C19) Efavirenz (CYP2B6) S-Warfarin (CYP2C9) Effect of BI AUC GMR Study in healthy volunteers (n=14-24); 240 mg BID BI Sabo JP et al ICAAC 2012 Abs A-1248

32 Thank you! Slide 32

Managing potential drug-drug interactions to achieve success in HCV triple therapy. David Back University of Liverpool

Managing potential drug-drug interactions to achieve success in HCV triple therapy. David Back University of Liverpool Managing potential drug-drug interactions to achieve success in HCV triple therapy David Back University of Liverpool Understanding the metabolic pathways of DAAs Drug CYP 3A4 P-gp Telaprevir Boceprevir

More information

Drug-Drug Interactions in the Treatment of Hepatitis C

Drug-Drug Interactions in the Treatment of Hepatitis C Drug-Drug Interactions in the Treatment of Hepatitis C Jennifer J. Kiser, PharmD University of Colorado Denver Department of Pharmaceutical Sciences May 11, 2013 Disclosures Jennifer Kiser receives or

More information

Understanding Pharmacokinetic Variability and Managing Drug Interactions

Understanding Pharmacokinetic Variability and Managing Drug Interactions Understanding Pharmacokinetic Variability and Managing Drug Interactions Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious Diseases

More information

HCV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, April 2014.

HCV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, April 2014. Page 1 HCV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, April 2014. This report summarises interaction studies relating

More information

Management of Drug-drug Interactions in Hepatitis C Therapy

Management of Drug-drug Interactions in Hepatitis C Therapy Management of Drug-drug Interactions in Hepatitis C Therapy David M. Burger Professor of Clinical Pharmacy Radboud University Nijmegen Medical Center The Netherlands IDPharmacology@akf.umcn.nl A case to

More information

Direct antiviral therapy of hcv and relevant drug drug interactions for ivdu

Direct antiviral therapy of hcv and relevant drug drug interactions for ivdu Direct antiviral therapy of hcv and relevant interactions for ivdu Stefan Mauss Center for HIV and Hepatogastroenterology Duesseldorf, Germany Disclosures Advisory board: Abbvie, BMS, Boehringer Ingelheim,

More information

Pharmacodynamics and Drug-Drug Interactions in HCV/HIV Co-Infected Persons on Treatment with DAAs

Pharmacodynamics and Drug-Drug Interactions in HCV/HIV Co-Infected Persons on Treatment with DAAs Pharmacodynamics and Drug-Drug Interactions in HCV/HIV Co-Infected Persons on Treatment with DAAs Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and

More information

Drug drug interaction of new HCV drugs

Drug drug interaction of new HCV drugs Drug drug interaction of new HCV drugs Stefano Bonora University of Torino Disposition of old DAAs Drug Dosing regimen CYP P-glycoprotein Non-CYP metabolism Telaprevir Q8h No significant boosting by RTV

More information

Slide 1 HIV/ HCV Coinfected people: what are the specific concerns they face?

Slide 1 HIV/ HCV Coinfected people: what are the specific concerns they face? Slide 1 HIV/ HCV Coinfected people: what are the specific concerns they face? Marion Peters MD University of California San Francisco 2011 Slide 2 Special issues Effect of HIV on HCV Effects of HCV on

More information

Meeting Report 15 th PK Workshop, Washington, 2014 Produced by www.hiv-druginteractions.org

Meeting Report 15 th PK Workshop, Washington, 2014 Produced by www.hiv-druginteractions.org Page 1 of 7 HIV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and HCV Therapy, Washington, April 2014. This report summarises interaction studies relating

More information

Herta Crauwels, et al.: Rilpivirine Drug-Drug Interactions

Herta Crauwels, et al.: Rilpivirine Drug-Drug Interactions AIDS Rev. 2013;15:87 101 Herta Crauwels, et al.: Rilpivirine Drug-Drug Interactions Clinical Perspective on Drug Drug Interactions with the Non-nucleoside Reverse Transcriptase Inhibitor Rilpivirine Herta

More information

Managing Drug Interactions in Hepatitis C: A Case-Based Approach

Managing Drug Interactions in Hepatitis C: A Case-Based Approach Managing Drug Interactions in Hepatitis C: A Case-Based Approach Alice Tseng PharmD, FCSHP, AAHIVP Toronto General Hospital May 30 th, 2012 Objectives Review principles of drug interactions Understand

More information

EACS 2013. Dominique Braun Universitätsspital Zürich

EACS 2013. Dominique Braun Universitätsspital Zürich EACS 2013 Switch data Rilpivirine: Swing-trial Elvitegravir: Flamingo-trial Simplification Dual-Therapy: LPV/r + 3TC in the Gardel-trial Mono-Therapy: Darunavir/r mono in clinical setting Boceprevir/Telaprevir

More information

Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total

Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n

More information

Perspective Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment

Perspective Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment Perspective Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment Direct-acting antiviral (DAA) drugs exhibit considerable variability in mechanisms of metabolism

More information

Management of HIV/HCV Co-infected Patients

Management of HIV/HCV Co-infected Patients Management of HIV/HCV Co-infected Patients David Wyles, MD Associate Professor of Medicine Division of Infectious Diseases University of California, San Diego San Diego, California Disclosures Grants/Research

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy

More information

London Therapeutic Tender Implementation: Guidance for Clinical Use. 4 th June 2014 FINAL

London Therapeutic Tender Implementation: Guidance for Clinical Use. 4 th June 2014 FINAL London Therapeutic Tender Implementation: Guidance for Clinical Use 4 th June 2014 FINAL Contents 3. General principles 4. Financial impact of therapeutic tendering for branded ARVs 5. London ARV algorithm:

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked

More information

DRUG INTERACTIONS WITH NEW/INVESTIGATIONAL HEPATITIS C NS5A INHIBITORS. Ledipasvir (LDV, GS-5885) Gilead. 90 mg once daily

DRUG INTERACTIONS WITH NEW/INVESTIGATIONAL HEPATITIS C NS5A INHIBITORS. Ledipasvir (LDV, GS-5885) Gilead. 90 mg once daily DRUG INTERACTIONS WITH NEW/INVESTIGATIONAL HEPATITIS C NS5A INHIBITORS Pharmacology Adult Dose NS5A replication complex inhibitor Approved in Japan and the EU: 60 mg once daily NS5A inhibitor NS5A inhibitor

More information

Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA

Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive

More information

HIV/Hepatitis C co-infection. Update on treatment Eoin Feeney

HIV/Hepatitis C co-infection. Update on treatment Eoin Feeney HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What

More information

The question and answer session is not available after the live webinar.

The question and answer session is not available after the live webinar. 1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments

More information

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052)

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052) Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C PIs: atazanavir PIs: other Simeprevir with ritonavir- or cobicistat boosted PIs (significant simeprevir AUC).

More information

Viral Hepatitis Prevention Board Meeting November 2013. The Netherlands: Hepatitis C treatment guidelines

Viral Hepatitis Prevention Board Meeting November 2013. The Netherlands: Hepatitis C treatment guidelines Viral Hepatitis Prevention Board Meeting November 2013 The Netherlands: Hepatitis C treatment guidelines Floor Berden MD, PhD student Radboud university medical center Nijmegen, the Netherlands Conflicts

More information

Drug Interactions in Managing HIV/HCV Co-Infection Presenter: Christopher Keeys, Pharm.D., BCPS 28 October 2015

Drug Interactions in Managing HIV/HCV Co-Infection Presenter: Christopher Keeys, Pharm.D., BCPS 28 October 2015 Drug Interactions in Managing HIV/HCV Co-Infection Presenter: Christopher Keeys, Pharm.D., BCPS 28 October 2015 Drug-Drug Interactions between Direct Acting Antiviral (DAA) and Antiretroviral Therapy (ART)

More information

Expectations for HCV Therapy with Small Molecules: An Activist Perspective

Expectations for HCV Therapy with Small Molecules: An Activist Perspective Expectations for HCV Therapy with Small Molecules: An Activist Perspective Tracy Swan, Treatment Action Group Second International Symposium on Hepatitis Care in Substance Users September 15-16, 2011 Brussels,

More information

Treating HIV in children with tuberculosis

Treating HIV in children with tuberculosis International AIDS Society - Industry Liaison Forum Meeting 5 March 2012 Treating HIV in children with tuberculosis Helen McIlleron, Division of Clinical Pharmacology University of Cape Town Challenges

More information

Current Opinion in Hepatitis C Treatment

Current Opinion in Hepatitis C Treatment White Nights of Hepatology 2011 Current Opinion in Hepatitis C Treatment George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University

More information

New treatment options for HCV: implications for the Optimal Use of HCV Assays

New treatment options for HCV: implications for the Optimal Use of HCV Assays New treatment options for HCV: implications for the Optimal Use of HCV Assays Hans Orlent Dept. of Gastroenterology & Hepatology AZ Sint Jan Brugge-Oostende, Brugge This program is supported by educational

More information

Navigating the Drug Interactions with New HCV Regimens

Navigating the Drug Interactions with New HCV Regimens Navigating the Drug Interactions with New HCV Regimens Jennifer J. Kiser, PharmD Associate Professor University of Colorado jennifer.kiser@ucdenver.edu May 8, 2015 Objectives Identify potential drug interactions

More information

ZEPATIER (elbasvir and grazoprevir) tablets, for oral use Initial U.S. Approval: 2016

ZEPATIER (elbasvir and grazoprevir) tablets, for oral use Initial U.S. Approval: 2016 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZEPATIER safely and effectively. See full prescribing information for ZEPATIER. ZEPATIER (elbasvir

More information

Rhinivirus - Cancer Treatment

Rhinivirus - Cancer Treatment 16 th Annual Conference of the National HIV Nurses Association (NHIVNA) Susan Kidger North Manchester General Hospital 26-27 June 2014- City Hall, Cardiff 2 nd Generation Treatment for Hepatitis C and

More information

----------------------DOSAGE FORMS AND STRENGTHS--------------------- HIGHLIGHTS OF PRESCRIBING INFORMATION

----------------------DOSAGE FORMS AND STRENGTHS--------------------- HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OLYSIO safely and effectively. See full prescribing information for OLYSIO. OLYSIO (simeprevir) capsules,

More information

Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir

Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir Research Article Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir Rajeev M. Menon, Prajakta S. Badri, Tianli Wang, Akshanth

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C Second Generation Antivirals Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Hepatitis C Second Generation Antivirals Through Preferred

More information

Victrelis: hints for success. Katarnya Gilbert Hepatology MSL MSD

Victrelis: hints for success. Katarnya Gilbert Hepatology MSL MSD Victrelis: hints for success Katarnya Gilbert Hepatology MSL MSD 1 Some Facts: BOC has no clinically significant activity against other HCV genotypes. Resistance with protease inhibitor monotherapy can

More information

Debate: To Treat Now or Not to Treat Now. Age, Disease Stage, Resistance, and Comorbidities

Debate: To Treat Now or Not to Treat Now. Age, Disease Stage, Resistance, and Comorbidities Debate: To Treat Now or Not to Treat Now Age, Disease Stage, Resistance, and Comorbidities Moderator: Raymond T. Chung, MD Associate Professor of Medicine, Harvard Medical School Director of Hepatology

More information

Request for Prior Authorization HEPATITIS C TREATMENTS

Request for Prior Authorization HEPATITIS C TREATMENTS IA Medicaid Member ID # Patient name DOB FAX Completed Form To 1 (800) 574-2515 Provider Help Desk 1 (877) 776-1567 Patient address Patient phone Provider NPI Prescriber name Phone Prescriber address Fax

More information

This lecture offers theoretical and practical information about drug interactions in antiretroviral therapy.

This lecture offers theoretical and practical information about drug interactions in antiretroviral therapy. Drug interactions Institute of Tropical Medicine, Antwerpen, October 2007 Learning objectives This lecture offers theoretical and practical information about drug interactions in antiretroviral therapy.

More information

VICTRELIS (boceprevir) capsules, for oral use Initial U.S. Approval: 2011

VICTRELIS (boceprevir) capsules, for oral use Initial U.S. Approval: 2011 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VICTRELIS safely and effectively. See full prescribing information for VICTRELIS. VICTRELIS (boceprevir)

More information

Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C

Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Debra Birnkrant, MD Director, DAVP DILI Conference March 20, 2013 1 HCV in the United States 3 to 4 million people have chronic HCV

More information

INCIVEK (telaprevir) tablets, for oral use Initial U.S. Approval: 2011

INCIVEK (telaprevir) tablets, for oral use Initial U.S. Approval: 2011 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INCIVEK safely and effectively. See full prescribing information for INCIVEK. INCIVEK (telaprevir)

More information

Clinical management of drug drug interactions in HCV therapy: Challenges and solutions

Clinical management of drug drug interactions in HCV therapy: Challenges and solutions Clinical management of drug drug interactions in HCV therapy: Challenges and solutions David Burger 1,, David Back 2, Peter Buggisch 3, Maria Buti 4, Antonio Craxí 5, Graham Foster 6, Hartwig Klinker 7,

More information

Managing HIV Patients with Cardiac Disease: How to Avoid Going Into Heart Failure (the clinician, not the patient)

Managing HIV Patients with Cardiac Disease: How to Avoid Going Into Heart Failure (the clinician, not the patient) Managing HIV Patients with Cardiac Disease: How to Avoid Going Into Heart Failure (the clinician, not the patient) Alice Tseng, Pharm.D., FCSHP, AAHIVP April 25, 2015 Higher Prevalence of Age-Related

More information

Interactions Between Antiretrovirals and Antiplatelet Agents and Novel Oral Anticoagulants

Interactions Between Antiretrovirals and Antiplatelet Agents and Novel Oral Anticoagulants Dosing Metabolism Clopidogrel (Plavix ) 300mg 600mg loading dose 75 mg daily maintenance dose Prodrug activated by CYP2C19 (major), CYP2B6 & metabolism. CYP2B6. 1 Prasugrel (Effient ) 60mg loading dose

More information

Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP

Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP I do not have any relevant financial relationships with any commercial interests. At the end of

More information

PHARMACY PRIOR AUTHORIZATION

PHARMACY PRIOR AUTHORIZATION PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization

More information

NEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)

NEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical

More information

Innovazione farmacologica e farmacologia clinica

Innovazione farmacologica e farmacologia clinica Innovazione farmacologica e farmacologia clinica Francesco Scaglione, MD, PhD Department of Medical Biotechnology and Translational Medicine School of medicine Postgradute School of clinical pharmacology

More information

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 7/2015

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 7/2015 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DAKLINZA safely and effectively. See full prescribing information for DAKLINZA. tablets, for oral

More information

Management of HIV and TB Co-infection in South Africa

Management of HIV and TB Co-infection in South Africa Management of HIV and TB Co-infection in South Africa Halima Dawood Department of Medicine Case Report 39 yr old female Referred to clinic on 14/06/2006 for consideration to commence antiretroviral therapy

More information

A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients

A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients CONCISE REVIEW Drug interactions with boceprevir and telaprevir., 2012; 11 (2): 179-185 March-April, Vol. 11 No.2, 2012: 179-185 179 A review of drug interactions with boceprevir and telaprevir: implications

More information

Post AASLD Update in HCV Torino, 10 Gennaio 2013. Fattori che possono influenzare il trattamento: RVR e Lead in

Post AASLD Update in HCV Torino, 10 Gennaio 2013. Fattori che possono influenzare il trattamento: RVR e Lead in Post AASLD Update in HCV Torino, 10 Gennaio 2013 Fattori che possono influenzare il trattamento: RVR e Lead in Alessia Ciancio Università di Torino Città della Salute e delle Scienze Will predictors usefull

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Drug Interaction Studies Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations DRAFT GUIDANCE This guidance document is being distributed for comment

More information

Drug Interactions with Smoke and Smoking Cessation Medications

Drug Interactions with Smoke and Smoking Cessation Medications Drug Interactions with Smoke and Smoking Cessation Medications Paul Oh MD MSc FRCPC FACP Medical Director, Toronto Rehab Assistant Professor, Division of Clinical Pharmacology, University of Toronto Disclosures

More information

Drug-Drug Interactions with Antiretroviral Therapy. Case-Based Discussions

Drug-Drug Interactions with Antiretroviral Therapy. Case-Based Discussions Drug-Drug Interactions with Antiretroviral Therapy Case-Based Discussions Alice K. Pau, Pharm.D. Staff Scientist (Clinical) Clinical Pharmacy Specialist DCR/NIAID/NIH Learning Objectives Upon completion

More information

Robert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012

Robert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012 Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public

More information

New anticoagulants: Monitoring or not Monitoring? Not Monitoring

New anticoagulants: Monitoring or not Monitoring? Not Monitoring The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and

More information

Preamble. Introduction. Marc G. Ghany, 1 David R. Nelson, 2 Doris B. Strader, 3 David L. Thomas, 4 and Leonard B. Seeff 5 *

Preamble. Introduction. Marc G. Ghany, 1 David R. Nelson, 2 Doris B. Strader, 3 David L. Thomas, 4 and Leonard B. Seeff 5 * An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases A new section on Use and Interpretation of

More information

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON

More information

EASL Recommendations on Treatment of Hepatitis C 2015

EASL Recommendations on Treatment of Hepatitis C 2015 EASL on Treatment of Hepatitis C 2015 European Association for the Study of the Liver Introduction Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide [1]. The

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare

More information

When should in vivo transportermediated drug-drug interaction studies be conducted? A scientific perspective

When should in vivo transportermediated drug-drug interaction studies be conducted? A scientific perspective Science at Sunrise, March 7, 2015 When should in vivo transportermediated drug-drug interaction studies be conducted? A scientific perspective Lei Zhang, Ph.D. Office of Clinical Pharmacology Office of

More information

17/01/14. What are special patient groups? Management of hepatitis C in special patient groups. Management of hepatitis C in

17/01/14. What are special patient groups? Management of hepatitis C in special patient groups. Management of hepatitis C in Management of hepatitis C in special patient groups Minisymposium Challenges in viral hepatitis 14 Lausanne 16.1.14 B. Müllhaupt Gastroenterology and Hepatology Swiss HPB- and Transplant-Center University

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating

More information

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr HOLKIRA PAK ombitasvir/paritaprevir/ritonavir film-coated tablets (12.5/75/50 mg) and dasabuvir (as dasabuvir sodium monohydrate) film-coated

More information

HIV/HCV Co-Infection

HIV/HCV Co-Infection HIV/HCV Co-Infection 2015 Kentucky Conference on Viral Hepatitis Matt Cave, M.D. Associate Professor Department of Medicine Division of Gastroenterology, Hepatology, & Nutrition Department of Pharmacology

More information

HCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre

HCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV

More information

MEDICAL POLICY STATEMENT

MEDICAL POLICY STATEMENT MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements

More information

Management of HCV Treatment-related Side-effects, Toxicity, and Drug-interactions

Management of HCV Treatment-related Side-effects, Toxicity, and Drug-interactions North American Journal of Medicine and Science Jan 2014 Vol 7 No.1 33 Review Management of HCV Treatment-related Side-effects, Toxicity, and Drug-interactions Jenna K. Kawamoto, PharmD; 1 Jason P. Smith,

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

CANDIDA INFECTIONS - TREATMENT GUIDELINES IN ADULT

CANDIDA INFECTIONS - TREATMENT GUIDELINES IN ADULT Page 1 of 6 TITLE: PATIENTS CANDIDA INFECTIONS - TREATMENT GUIDELINES IN ADULT GUIDELINES: These are the 2011 Guidelines for the Treatment of Candida species infections in adult patients. These recommendations

More information

CHAPTER 2B HIV DRUG-DRUG INTERACTIONS I. INTRODUCTION GENERAL RECOMMENDATIONS:

CHAPTER 2B HIV DRUG-DRUG INTERACTIONS I. INTRODUCTION GENERAL RECOMMENDATIONS: CHAPTER 2B HIV DRUG-DRUG INTERACTIONS I. INTRODUCTION II. GENERAL RECOMMENDATIONS: The practitioner should conduct a thorough medication history at each visit that includes prescription medications, over-the-counter

More information

Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients

Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Second Silibinin Workshop, Cologne, 23 rd May 2014 Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Dominique L Braun, MD Division of

More information

Summary of the risk management plan (RMP) for Cerdelga (eliglustat)

Summary of the risk management plan (RMP) for Cerdelga (eliglustat) EMA/743948/2014 Summary of the risk management plan (RMP) for Cerdelga (eliglustat) This is a summary of the risk management plan (RMP) for Cerdelga, which details the measures to be taken in order to

More information

The hepatitis community has eagerly awaited regulatory

The hepatitis community has eagerly awaited regulatory REVIEW Review and Management of Drug Interactions With Boceprevir and Telaprevir Jennifer J. Kiser, 1 James R. Burton, 2 Peter L. Anderson, 1 and Gregory T. Everson 2 Boceprevir (BOC) and telaprevir (TPV),

More information

Update on hepatitis C: treatment and care and future directions

Update on hepatitis C: treatment and care and future directions Update on hepatitis C: treatment and care and future directions Professor Greg Dore Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New

More information

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and AAC Accepted Manuscript Posted Online 12 October 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.01778-15 Copyright 2015 Badri et al. This is an open-access article distributed under the terms of the

More information

Treatment Options for Hepatitis C in the Post Transplant Patient

Treatment Options for Hepatitis C in the Post Transplant Patient Treatment Options for Hepatitis C in the Post Transplant Patient Caroline Rochon, MD, FACS,FRCSC Transplant and Hepatobiliary Surgery Hartford Hospital Assistant Professor of Surgery, University of Connecticut

More information

Back to main HCV Drug Development Section. December 2012. By Tracy Swan

Back to main HCV Drug Development Section. December 2012. By Tracy Swan Submitted by tracyswan on Wed, 12/12/2012-20:09 Back to main HCV Drug Development Section December 2012 By Tracy Swan It is difficult to be anything other than dazzled by astounding cure rates of up to

More information

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications Infect Dis Ther (2015) 4:159 172 DOI 10.1007/s40121-015-0061-2 REVIEW Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Kirpal Kaur. Mona A. Gandhi. Judianne Slish

More information

Managing Drug Interactions in Transplant Recipients

Managing Drug Interactions in Transplant Recipients Managing Drug Interactions in Transplant Recipients David J. Quan, Pharm.D., BCPS Clinical Pharmacist Clinical Professor of Pharmacy Department of Pharmaceutical Services UCSF Medical Center Goals and

More information

Review of The Most Common Drug-Drug Interactions in HIV Infected Patients. Rodolphe Garraffo (FRANCE)

Review of The Most Common Drug-Drug Interactions in HIV Infected Patients. Rodolphe Garraffo (FRANCE) Review of The Most Common Drug-Drug Interactions in HIV Infected Patients Rodolphe Garraffo (FRANCE) The terms of the problem? The HIV infected patients live longer, but, doing so, they develop earlier

More information

HARVONI (ledipasvir and sofosbuvir) tablets, for oral use Initial U.S. Approval: 2014

HARVONI (ledipasvir and sofosbuvir) tablets, for oral use Initial U.S. Approval: 2014 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HARVONI safely and effectively. See full prescribing information for HARVONI. HARVONI (ledipasvir

More information

Warfarin and boceprevir interaction causing subtherapeutic international normalized ratio: a case report

Warfarin and boceprevir interaction causing subtherapeutic international normalized ratio: a case report Tsiattalos and Patel Journal of Medical Case Reports 2014, 8:433 JOURNAL OF MEDICAL CASE REPORTS CASE REPORT Open Access Warfarin and boceprevir interaction causing subtherapeutic international normalized

More information

LIVER FUNCTION TESTS AND STATINS

LIVER FUNCTION TESTS AND STATINS LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:338 341 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated

More information

HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain

HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening

More information

Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary

Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary This program applies to Health Insurance Marketplace, FlexRx

More information

The following should be current within the past 6 months:

The following should be current within the past 6 months: EVALUATION Baseline Labs Obtain at time or prior to initial evaluation CBC with diff PT/INR CMP HCV Genotype (obtained PRIOR TO consult visit) HCV RNA (obtained PRIOR TO consult visit) Hep A IgG Hep BsAg,

More information

Daclatasvir (Daklinza)

Daclatasvir (Daklinza) FACTSHEET Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in

More information

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment

More information

An Update on the Treatment of Hepatitis C

An Update on the Treatment of Hepatitis C An Update on the Treatment of Hepatitis C Audrey Broyer, Pharm D, CGP Clinical Pharm acy Specialist Manchester VA Medical Center Disclosure Statement I have no relevant financial relationships that would

More information

High Blood Cholesterol

High Blood Cholesterol National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour

More information

Treatment of Chronic Hepatitis C - September 2015 Update

Treatment of Chronic Hepatitis C - September 2015 Update Treatment of Chronic Hepatitis C - September 2015 Update Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Written by: Beat Müllhaupt, Andri Rauch, Jan Fehr and Darius

More information

Management of HCV/HIV co-infection in the era of DAA-based therapy

Management of HCV/HIV co-infection in the era of DAA-based therapy Management of HCV/HIV co-infection in the era of DAA-based therapy Jürgen K. Rockstroh Department of Internal Medicine I University Hospital Bonn Germany Conflict of interest I have received honoraria

More information

EASL Recommendations on Treatment of Hepatitis C 2015 SUMMARY

EASL Recommendations on Treatment of Hepatitis C 2015 SUMMARY JULY 2015 EASL Recommendations on Treatment of Hepatitis C 2015 Contents SUMMARY 1. Diagnosis of acute and chronic hepatitis C 2. Screening for chronic hepatitis C 3. Goals and endpoints of HCV therapy

More information

HCV Pipeline: The Next 18 Months Michael W. Fried, MD

HCV Pipeline: The Next 18 Months Michael W. Fried, MD HCV Pipeline: The Next 18 Months Michael W. Fried, MD Professor of Medicine Director, UNC Liver Center University of North Carolina at Chapel Hill Michael W. Fried, MD Commercial Disclosures Grants/Research

More information